Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes

Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration with Acepodia and faces mounting lawsuits over its contraceptive, Depo-Provera. The decision to mutually terminate the partnership with Acepodia, which focused on autoimmune disease drug development, is attributed to PFE’s global resource prioritization and not to Acepodia’s capabilities.

The wind-down is expected to have no impact on Acepodia’s clinical programs, with both companies leaving open the possibility of future collaboration.

Pixabay/Public Domain

Simultaneously, Pfizer Inc. (NYSE:PFE) is embroiled in multidistrict litigation involving approximately 400 lawsuits alleging the company failed to adequately warn about the risk of brain tumors linked to long-term Depo-Provera use. Recent studies have intensified scrutiny, and hearings are scheduled as the company faces accusations of prioritizing profits over patient safety.

Despite these challenges, Pfizer Inc. (NYSE:PFE)’s performance has remained stable, mirroring broader market trends. However, investor sentiment is cautious: the company’s total shareholder return fell 11.11% over the past year, underperforming the US pharmaceuticals sector’s 10.5% decline. Analysts note that the current share price reflects these uncertainties, with only a marginal upside projected, underscoring the importance of future earnings and revenue growth for PFE’s outlook.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.